Havih Envirosciences, a subsidiary of Maxwell Biosciences, announces a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities, supporting branded innovation, India-based IP creation and high-skill job growth.

Havih Envirosciences, a Maxwell Biosciences subsidiary, partners with the Government of Andhra Pradesh to build advanced pharma R&D, create India-based IP and support the shift beyond generics.

Former US Congressman Dr. Brad Wenstrup joins Maxwell Biosciences Board of Directors. Dr. Wenstrup has broad experience in government, military and civilian medicine and expertise in managing bacterial, fungal and viral infections, key to Maxwell’s vision to create health for the world.

Maxwell Biosciences marks its company holiday, Scientist Appreciation Day, with a call to recognize scientists and connect with underfunded, visionary researchers.

Maxwell Biosciences raises $20M to launch Claromer™ clinical trials and expand AI-driven R&D, targeting infectious disease without harming the microbiome.

Maxwell Biosciences, a global health technology company pioneering immune-inspired small molecules called Claromers™, today announced new engineering leadership for its Artificial Intelligence efforts—further cementing its decade-long commitment to AI-first innovation.

Maxwell Biosciences announces its entry into the global cosmetics market through strategic partnerships and licensing deals. Its Claromer™ technology—engineered to support the skin microbiome—is now being tested by leading skincare companies seeking next-generation, immune-inspired solutions.

Maxwell Biosciences announces our 7th cooperative agreement with the US military to test Claromers™ for the treatment and prevention of diarrheal disease.

Discover how Maxwell Biosciences is advancing biodefense with its Claromer™ platform in an exclusive Contract Pharma interview. CEO Joshua McClure discusses U.S. Military partnerships, a $3M MTEC award and innovative therapeutics for infectious diseases like Dengue Fever.

Austin, Texas--(Newsfile Corp. - October 24, 2024) - Maxwell Biosciences is developing a new type of anti-infective drug designed to improve upon natural immune system peptides. The company announced today it has been selected to receive a nearly $3M award from the Medical Technology Enterprise Consortium (MTEC). MTEC works in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and the U.S. Department of Defense.

Maxwell Biosciences, a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors. This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.

Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases. In this study, the researchers showed how a group of novel molecules - inspired by the human immune system - inactivates several viruses, including all tested Influenza, Coronavirus, Hepatitis, Herpes, Zika and Chikungunya strains. Their approach may lead to drugs that can be used against many viruses, and help overcome wide-ranging challenges with antimicrobial drug resistance.